Whole-body PBPK model of voriconazole as CYP2C19 substrate (pharmacogenomics analysis) and usalke as CYP3A4 perpetrator drug

Within this repository, we distribute a PK-Sim project file containing simulations of a published clinical study used to evaluate the descriptive and predictive performance of the voriconazole model, including the observed data digitized from literature reports. The voriconazole model has been published previously [1]. Additionally, a PK-Sim snapshot (*.json) file of the current PBPK model created with PK-Sim version 9.1 is provided.

PK-Sim Version 9.1.

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

The model is distributed under the GPLv2 Lincense.

[1] Li X, Frechen S, Moj D, Lehr T, Taubert M, Hsin C-H, Mikus G, Neuvonen PJ, Olkkola KT, Saari TI, Fuhr U. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions. Clin. Pharmacokinet. 2020; 59, 781–808